REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Chemistry: Natural Resins Or Derivatives; Peptides Or Proteins; Lignins Or Reaction Products Thereof > Proteins, I.e., More Than 100 Amino Acid Residues > Lymphokines, E.g., Interferons, Interlukins, Etc. Lymphokines, E.g., Interferons, Interlukins, Etc.Lymphokines, E.g., Interferons, Interlukins, Etc. patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/11/07 - 20070010660 - G-csf conjugates Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo ... 01/11/07 - 20070010659 - Adiponectin variants An adiponectin variant with one or more amino acid modifications relative to a corresponding parent adiponectin, wherein the solubility of the variant is improved by at least 3-fold relative to residues 110-244 of human adiponectin. ... 01/04/07 - 20070004906 - Novel antagonists of mcp proteins Novel antagonists of MCP proteins, in particular of MCP-1 protein, can be obtained by generating MCP mutants whose GAG binding site, located at the N-terminal of MCP proteins, is eliminated following non-conservative substitutions. Compounds prepared in accordance with the present invention can be used in the treatment or prevention of ... 12/21/06 - 20060287505 - Mammalian cytokine-like polypeptide-10 A mammalian cytokine-like polypeptide, called Mammalian Cytokine-like polypeptide-10, (Zcyto10), polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets. ... 11/02/06 - 20060247422 - Chemically modified g-csf (n = 0 or 1) ... 10/26/06 - 20060241286 - Novel peptides and the application thereof in therapy Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angströms from an atom of the receptor corresponding to said ... 09/14/06 - 20060205926 - Cytokine polypeptides and antibodies containing a signal sequence for the attachement of glycosylphosphatidylinositol The invention relates to chimeric recombinant polypeptides, preferably therapeutic polypeptides, for example cytokines or antibodies, which are engineered to include a signal sequence for the attachment of glycosylphosphatidylinositol; cells expressing said polypeptides and methods to manufacture said polypeptides. ... 08/31/06 - 20060194952 - Enhancing the circulating half-life of antibody-based fusion proteins Disclosed are methods for the genetic construction and expression of antibody-based fusion proteins with enhanced circulating half-lives. The fusion proteins of the present invention lack the ability to bind to immunoglobulin Fc receptors, either as a consequence of the antibody isotype used for fusion protein construction, or through directed mutagenesis ... 08/31/06 - 20060194951 - Polynucleotides encoding interferon gamma polypeptides A conjugate exhibiting interferon gamma activity and comprising at least one first non-polypeptide moiety covalently linked to an IFG polypeptide, the polypeptide comprising an amino acid sequence that differs from that of a parent IFNG polypeptide in at least one introduced and/or at least one removed amino acid residue comprising ... 08/03/06 - 20060173167 - Process for the purification of recombinant polypeptides This invention relates to a method for purification of a recombinant polypeptide of interest, which polypeptide upon expression has been secreted into the periplasm of a transformed host cell. ... 07/06/06 - 20060149039 - Pseudo-native chemical ligation The present invention concerns methods and compositions for extending the technique of native chemical ligation to permit the ligation of a wider range of peptides, polypeptides, other polymers and other molecules via an amide bond. The invention further provides methods and uses for such proteins and derivatized proteins. The invention ... 06/29/06 - 20060142549 - Method of purifying protein Problems to be Solved: The present invention provides a simpler and less expensive method for purifying physiologically active proteins, especially antibodies, which can ensure removal of impurities such as DNA contaminants and viruses, and which can minimize a loss of physiologically active proteins. Means for Solving the Problems: A method ... 04/20/06 - 20060084793 - G-csf polypeptides and conjugates The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at ... 03/16/06 - 20060058511 - Method for stabilizing protein solution preparation Problems to be Solved: The present invention provides a method for improving the stability of protein solution formulations by suppressing the formation of associated matter from physiologically active proteins (e.g., antibodies, enzymes, hormones, cytokines) in a solution form. Means for Solving the Problems: A method for stabilizing a protein solution ... 02/16/06 - 20060036080 - Conjugates of gm-csf moiety and a polymer Conjugates of a GM-CSF moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions comprising conjugates to a patient. ... 01/26/06 - 20060020116 - Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated ... 12/22/05 - 20050283000 - Process for the production of a heterologous protein The invention relates to a new process for the production of a biologically active heterologous protein. The process involves the performance of biosynthesis by adjusting conditions in such a way that the process enables the accumulation of correctly folded precursor of the heterologous protein already in inclusion bodies. The invention ... 10/27/05 - 20050240010 - Nucleic acids encoding antagonists of interleukin-15 Disclosure herein are mutant IL-15 polypeptides and methods for using these polypeptides to modulate the immune response in a patient. ... 08/04/05 - 20050171338 - Mammalian tribbles signaling pathways and methods and reagents related thereto The invention provides methods and reagents for modulating mitogen activated protein kinase pathways using mammalian tribbles homologs (htrb). ... 07/21/05 - 20050159590 - Variants of interleukin-1 receptor antagonist: compositions and uses thereof The present invention provides Interleukin-1 receptor antagonist splice variants, including isolated nucleic acids encoding these variants and the encoded amino acid sequences, as well as antibodies, antisense oligonucleotides, expression vectors and host cells that include these sequences. The present invention further discloses methods of using these sequences in the diagnosis, ... 07/21/05 - 20050159589 - Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor The invention relates to the process for the isolation of biologically active granulocyte colony stimulating factor (G-CSF), which enables the separation of correctly folded biologically active monomeric molecules of G-CSF from the incorrectly folded, biologically inactive monomeric, oligo- or polymeric and also from aggregated molecules of G-CSF by using immobilized ... 06/30/05 - 20050143563 - Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue The present invention relates to a conjugate of a biocompatible polymer and a G-CSF bonded through a thiol group of a dysteine residue in G-CSF at a 1:1 molar ratio, and methods of preparation thereof. ... 06/23/05 - 20050137384 - Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit ... 06/16/05 - 20050131214 - Mammalian cytokine-like factor 7 Novel mammalian zcyto7 polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods including antibodies and anti-idiotypic antibodies. ... 06/16/05 - 20050131213 - Chromatographic separation of therapeutic polypeptides The present invention is directed to the purification and commercialization of therapeutic polypeptides that have. In one aspect of the invention, a method of purifying Interferon β-1b using size exclusion chromatography is provided. In another aspect of the invention, a method of purifying a polypeptide using size chromatography is provided. ... 06/09/05 - 20050124796 - Mouse cytokine receptor Cytokines and their receptors have proven usefulness in both basic research, animal models, and as therapeutics. The present invention provides a new cytokine receptor designated as “mouse Zcytor16,” which can bind and antagonize the IL-TIF cytokine. ... 06/02/05 - 20050119462 - Expression vectors and promoters for heterologous gene expression The present invention relates to novel vectors and nucleic acid sequences, which comprise promoters which are induced by nucleotides. The invention further relates to expression vectors utilising elements of the xanthosine operon and methods for the production of heterologous proteins. ... ### FreshPatents.com Support |